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The Medtronic-Hall valve was developed to improve on 
existing tilting disc valves by reducing the risk of valvular 
thrombosis. This was to be accomplished by improving 
the hemodynamics and by allowing the disc to move 
downstream away from the orifice during opening. The 
valve was also designed for maximal structural dura•
bility to minimize the risk of mechanical breakage. 
Before 1970, we primarily used ball valves and oscillating 
disc valves in the mitral position, At that time the rates of 
valve thrombosis and thromboembolism were rather dis•
turbing, When the Bjork-Shiley and Lillehei-Kaster valves 
appeared, it was our hope that the improved hemodynamics 
of the tilting disc design might reduce thromboembolism. 
The improved hemodynamics also seemed promising be•
cause most of the prosthetic valves then available did not 
sufficiently relieve patients with a stenotic valve and a small 
anulus. 
The Lillehei-Kaster and Bjork-Shiley valves differ in the 
opening angle of the disc, the area of the minor orifice and 
the presence or absence of disc overlap of the orifice in the 
closed position. We began a randomized comparison of 
these two valves in the early 1970s. This study included 
300 patients with an aortic valve prosthesis and 150 patients 
with a mitral valve prosthesis. Follow-up studies performed 
during the late 1970s (1-4) showed only small hemody•
namic differences between the two valve types in the larger 
sizes, but gradients for 21 and 23 mm valve sizes were 
significantly higher with the Lillehei-Kaster than with the 
Bjork-Shiley model. The linearized rate of thromboembol•
ism was about 3% per year for both groups of aortic valves, 
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With more than 1,000 Medtronic-Hall valves im•
planted since 1977, the clinical results have been very 
encouraging. The rates of thromboembolism and throm•
bosis are low, there have heen no mechanical failures 
and the hemodynamic function, especially with the smaller 
valves, is excellent. 
(J Am Coli CardioI1985;6:1417-21) 
compared with more than 6% per year for our aortic ball 
valves, although the latter were implanted during a previous 
time frame, which may have affected the results (5). There 
were no cases of mechanical failure with either of these 
tilting disc valve models, whereas we experienced fabric 
disruption with the cloth-covered ball valve and also some 
cases of worn poppets with the oscillating disc valve. 
New Valve Design 
Aortography and autopsy evidence indicated that the flow 
through the minor orifice behind the disc in the existing 
valves was not satisfactory, and it was in this location and 
where the disc touches the valve ring in the open position 
that thrombosis was likely to occur. Our goal was therefore 
to design a new tilting disc valve that would increase the 
size of the smaller orifice and would allow a sliding move•
ment of the disc away from the valve ring in its open po•
sition. We contacted Robert Kaster in Minneapolis and, after 
much planning and in vitro testing of prototypes, the result 
was the present Medtronic-Hall valve (6). 
Ideally, when completely open, the disc occluder would 
be at a 90° angle central to the orifice and out of the valve 
ring, leaving the opening of the valve completely unob•
structed. Of course, such a valve would not work because 
there would be almost no force vector for moving the disc 
to a closed position. We had to compromise, but insisted 
on obtaining a larger disc opening angle as well as upward 
disc mobility. The only practical design we found was one 
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Table 1. Medtronic-Hall Prostheses Implanted, by Position, 
From June 1977 to December 1984 
No. of No. of 
Valve Operation Patients Valves 
Isolated aortic 639 639 
Isolated mitral 155 155 
Pure double* 87 174 
Mixed doublet 48 48 
Total 929 1,016 
*Medtronic-Hall aortic and mitral valves. tMedtronic-Hall valve plus 
other type. 
that used a central guide rod, with a small clearance between 
the rod and the hole in the disc in the closed position. This 
design resulted in no more than 5% regurgitation of forward 
flow under any condition at any heart rate. In vitro tests 
showed a significant decrease in resistance to forward flow, 
and high speed cinematography showed that disc closure 
was very fast, which explained the low level of regurgitation. 
After mitral valve replacement in 42 dogs, it was con•
cluded that the valve worked well. There was no thrombus 
adhering to the struts or central hole, and there was no 
significant hemolysis. Therefore a program of clinical im•
plantation was begun. The first clinical implantation took 
place on June 6, 1977, when a 23 mm aortic valve was 
implanted in a 67 year old man. This man is now 74 years 
old and quite active. 
Methods 
Operative technique. A bubble oxygenator (Polystan) 
with I liter of St. Thomas cardioplegic solution is used 
initially and 300 mi is used every 30 minutes if aortic c1amp-
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ing time exceeds I hour. Suture technique in the mitral 
position usually consists of three mattress sutures of 2-0 
Mercilene (Dacron), with continuous sutures between the 
mattress sutures. Ifthe quality of the tissue is not favorable, 
pledget-reinforced Tycron (Teflon) sutures are used. In the 
aortic position, 2-0 Mercilene everting mattress sutures have 
generally been used. Modifications have been used in par•
ticular circumstances in some patients, including patients 
with infectious endocarditis. We used an in situ technique 
employing continuous sutures in the aortic position in more 
than 30 patients. Occasionally, simple interrupted sutures 
were also employed. 
Postoperative management. Patients are normally kept 
on ventilator support and standard antibiotic prophylaxis, 
using ampicillin and methicillin, for the first 18 hours. No 
heparin is used. Warfarin anticoagulation is started the day 
after operation. Lifelong anticoagulation is our standard 
treatment. We do not recommend altering this treatment in 
Scandinavia, where anticoagulation therapy works well with 
very few bleeding complications. 
Follow-up. One year after operation, all patients were 
readmitted to our department for follow-up studies including 
X-ray examination of the heart, echocardiography and Dop•
pler ultrasound. In some unselected patients we perform 
recatheterization. Thereafter, questionnaires are sent an•
nually to all patients. Patients are readmitted when com•
plications are suspected from replies to these inquiries. We 
have achieved 100% follow-up of our patients. Survival and 
event-free curves are calculated by the actuarial method (7) 
and compared by the method of Mantel (8). 
Hemodynamic assessment. To evaluate valve perform•
ance as early as possible, including the effect of valve ori•
entation within the anulus, we introduced the Aaslid (9) 
@ Size> 23mm 
® Size' 23mm 
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Figure 1. Actuarial survival curves, including 
operative deaths, of 581 patients with isolated 
aortic valve replacement. 
JACC Vol. 6, No.6 
December 1985:1417-21 
Figure 2. Actuarial survival curve, in•
eluding operative deaths, for 138 pa•
tients after isolated mitral valve replace•
ment. 
Figure 3. Actuarial survival curve, in-
eluding operative deaths, for 78 patients 
after isolated double valve replacement. 
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Table 2. Incidence of Systemic Embolism and Valvular Thrombosis 
Valve Follow-up 
Operation (pt-yr) 
Aortic 1,669 
Mitral 413 
Double 193 
pt-yr = patient years. 
No. of 
Events 
23 
7 
4 
Thromboembolism Valve Thrombosis 
Rate 
(per 100 
pt-yr) 
1.4 
I.7 
2.1 
Rate 
No. of (per I ()() 
Events pt-yr) 
0.1 
0.2 
0.5 
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Figure 4. Thromboembolism-free curves, including operative 
deaths, for 581 patients with aortic valve replacement (A VR) and 
138 with mitral valve replacement (MVR). 
method of measuring effective orifice area_ Simultaneous 
recordings of pressure and flow are obtained by employing 
an electromagnetic flow probe on the ascending aorta; the 
effective valve area is then calculated using the Bernoulli 
formula and the peak flow gradient. 
Results 
Mortality and survival. Since 1977 we have implanted 
1,016 Medtronic-Hall valves in 929 patients (Table 1). Op•
erative mortality was 9% for aortic valve replacement, 11 % 
for mitral valve replacement and 10% for combined aortic 
and mitral valve replacement. Causes of death were pump 
failure or septicemia in most cases, and valve-related deaths 
were not encountered. 
Actuarial late survival for patients with an aortic valve 
prosthesis depended on valve size (Fig. 1). Of patients with 
size 25 mm or larger valves, 84% were alive at 5 years 
compared with 75% of patients with size 23 mm or smaller 
valves (p = 0.06). Actuarial survival at 6 years was 69% 
for mitral valve replacement (Fig. 2) and 65% for double 
valve replacement (Fig. 3). 
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Thrombotic complications. The annual linearized rates 
of thromboembolism and valvular thrombosis were, re•
spectively, 1.4 and 0.1% for aortic valve replacement and 
1.7 and 0.2% for mitral valve replacement (Table 2). The 
actuarial thromboembolism-free rates at 6 years were 94 and 
89% for aortic and mitral valve replacement, respectively 
(Fig. 4). 
Mechanical failure. There were no cases of mechanical 
valve failure. 
Hemodynamics. Recatheterization studies were per•
formed in 71 patients from 3 to 12 months after surgery 
(Table 3). The peak to peak pressure gradient across the 
aortic valve averaged 10.1 mm Hg among 28 patients having 
a size 21 or 23 mm valve. Among 26 patients having a size 
25 or 27 mm valve, the average gradient was 3.4 mm Hg, 
and both patients with a size 29 mm valve had a gradient 
of O. The 15 patients with a size 27 mm or larger mitral 
valve showed a mean diastolic gradient of 3 mm Hg or less. 
Hemolysis. Hemolysis with the Medtronic-Hall valve 
was not clinically significant. Hemoglobin levels remained 
within the normal range. Values of serum lactate dehydro•
genase remained mostly within normal limits, comparable 
with the values we obtained with the Bjork-Shiley valve 
and significantly lower than the values we observed with 
the Starr-Edwards ball valve and the Lillehei-Kaster valve. 
Comments 
Advantages of the Medtronic-Hall valve. For larger 
valve sizes, we had previously found only slight differences 
among the Lillehei-Kaster, Bjork-Shiley and Medtronic-Hall 
valves, whereas in the small sizes significantly larger valve 
areas were found for the Medtronic-Hall valves. In the 21 
mm aortic valve we found a mean orifice area of 1.7 cm2 
for the Medtronic-Hall valve, 1.3 cm2 for the Bjork-Shiley 
valve and less than 1.3 cm2 for the Lillehei-Kaster valve 
(10). 
Postoperative recatheterization studies in the present se•
ries confirmed these excellent hemodynamic results for the 
Medtronic-Hall valve, as previously shown by intraopera•
tive studies (11). The superior hemodynamic results and 
low rates of thromboembolism and thrombosis observed 
with this valve (Table 2) may be explained by a typical 
Table 3. Postoperative Transvalvular Pressure Gradients 
Aortic 
Valve Size No. of 
(mm) Patients 
21 9 
23 19 
25 18 
27 8 
29 2 
31 
Gradient 
(mmHg) 
12.0 
9.2 
3.8 
2.5 
0 
No. of 
Patients 
3 
7 
5 
Mitral 
Gradient 
(mm Hg) 
3.0 
2.7 
2.0 
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Figure 5. Postoperative aortogram 
demonstrating blood flow through both 
major and minor orifices of the aortic 
valve prosthesis. 
postoperative aortogram (Fig. 5), which illustrates ample 
flow through both the larger and smaller orifices relative to 
the disc. 
Comparison with tissue valve prostheses. Our expe•
rience with tissue valves has been limited. We are still using 
the Carpentier-Edwards valve in fertile women and the 
Ionescu-Shiley valve in the right side of the heart in con•
duits. In the left side of the heart we no longer use tissue 
valves in the aortic position. Two years ago we started a 
randomized study comparing the Medtronic-Hall valve with 
the Carpentier-Edwards valve in isolated mitral valve re•
placement in patients more than 20 year~ of age. For double 
valves and patients aged less than 20 years we are using 
Medtronic-Hall valves exclusively in the mitral position. 
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